Bevacizumab Monoclonal Antibody from Canada
Bevacizumab (Avastin) is a humanized monoclonal antibody binding VEGF, used for colorectal and lung cancer treatments. HTS 3002.13.0010 covers this unmixed, biotech-produced immunological product not in retail packaging. It qualifies as a protein regulating immunological processes per chapter definitions.
Duty Rate — Canada → United States
100%
Rate breakdown
9903.04.60100%Pharmaceuticals: patented pharma articles — 100% floor rate
9903.05.860%Universal product exemption (U.S. note 52(b))
9903.05.900%Articles already subject to Section 232 (steel/aluminum/copper + derivatives, autos + parts, wood, medium/heavy vehicles + parts, semiconductors, patented pharma) — U.S. note 52(f)
Import Tips
• Include potency assay results (e.g
• VEGF binding) in documentation for CBP review
• For EU-origin, leverage mutual recognition agreements to streamline FDA pre-approval